AFFILIATIONS
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
ABSTRACT
Background:
Loss of Y chromosome (LOY) is a common age-related clonal hematopoietic alteration that frequently co-occurs with clonal hematopoiesis of indeterminate potential and has been associated with adverse clinical outcomes. In allogeneic hematopoietic stem cell transplantation (allo-HSCT), LOY may additionally attenuate H-Y antigen–mediated graft-versus-leukemia (GVL) effects. We aimed to investigate the impact of LOY on clinical outcomes after allo-HSCT.
Methods:
A retrospective analysis was conducted for 1119 patients who underwent allo-HSCT at the Institute of Hematology and Blood Disease Hospital from January 2022 to June 2025.
Results:
Among the 1,119 patients, 48 (4.29%) had LOY at initial diagnosis. The LOY group showed a inferior overall survival (OS) compared with the Y-present group (3-year OS, 58.6% vs. 78.0%; P = 0.051). Relapse-free survival (RFS) was significantly inferior in the LOY group (3-year RFS, 57.1% vs. 71.4%; P = 0.006), and the cumulative incidence of relapse (CIR) was significantly higher (3-year CIR, 23.2% vs. 15.0%; P = 0.032). No significant difference in the cumulative incidence of grade II–IV acute graft-versus-host disease (aGVHD) was observed between the LOY and Y-present groups (20.8% vs. 29.5%; P = 0.196). Among patients who underwent female-to-male allo-HSCT, those in the LOY group had significantly inferior OS and RFS compared with those in the Y-present group (3-year OS, 45.0% vs. 77.8%; P = 0.006; 3-year RFS, 46.7% vs. 73.3%; P = 0.002). The LOY group also showed a trend toward a higher CIR (3-year CIR, 26.7% vs. 13.6%; P = 0.084). No significant difference in the cumulative incidence of grade II–IV aGVHD was observed between the two groups (20.0% vs. 29.4%; P = 0.568). In contrast, LOY was not significantly associated with clinical outcomes among patients who underwent male-to-male allo-HSCT.
Conclusion:
LOY at initial diagnosis in male patients was associated with an increased risk of relapse and adverse survival outcomes after allo-HSCT, potentially due to an attenuated GVL effect. The adverse prognostic impact of LOY was predominantly observed in male recipients with female donors, suggesting that the donor-recipient sex combination may modulate LOY-associated post-transplant immune effects and clinical outcomes.
DISCLOSURES
Xueyao Li: No relevant conflicts of interest to declare.